A5059350004- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Erythropoietin and Anemia Treatment
- Monoclonal and Polyclonal Antibodies Research
- Biosimilars and Bioanalytical Methods
- Silicon Carbide Semiconductor Technologies
- Cancer, Lipids, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Transgenic Plants and Applications
- Nanowire Synthesis and Applications
- Virus-based gene therapy research
- Cancer Research and Treatments
- Iron Metabolism and Disorders
- Brain Metastases and Treatment
- CRISPR and Genetic Engineering
- Single-cell and spatial transcriptomics
- T-cell and B-cell Immunology
- Management of metastatic bone disease
Ludwig-Maximilians-Universität München
2021-2025
German Center for Lung Research
2020-2025
Technical University of Munich
2024-2025
Klinik und Poliklinik für Nuklearmedizin
2025
LMU Klinikum
2021-2024
German Cancer Research Center
2024
Center for Integrated Protein Science Munich
2021-2023
Amgen (United States)
1996
The combination of directed migration and immunosuppressive shielding enables effective T cell therapy in solid tumors.
Lung cancer patients are at risk for brain metastases and often succumb to their intracranial disease. Chimeric Antigen Receptor (CAR) T-cells emerged as a powerful cell-based immunotherapy hematological malignancies; however, it remains unclear whether CAR represent viable therapy metastases. Here, we established syngeneic orthotopic cerebral metastasis model in mice by combining chronic cranial window with repetitive intracerebral two-photon laser scanning-microscopy. This approach enabled...
Abstract Background Chimeric antigen receptor (CAR) T cell therapy has been successfully translated to clinical practice for the treatment of B malignancies. The suppressive microenvironment many malignancies is a bottleneck preventing success CAR cells in broader range tumours. Among others, immunosuppressive metabolite adenosine present high concentrations within tumours and dampens anti-tumour function immune consequently therapeutic response. Methods Here, we impact selective A2 A...
33 Background: PSMA-PET/CT is increasingly being used to monitor chemotherapy in prostate cancer and shows promise for predicting outcomes improving response evaluation. This retrospective study aimed determine the prognostic value of quantitative tumor burden parameters derived from overall survival (OS) during taxane-based chemotherapy. Methods: Databases 6 institutions were screened patients who underwent[ 68 Ga]Ga-PSMA11-PET serum PSA measurements at baseline within three months after...
Abstract Background In many situations, the therapeutic efficacy of CAR T cells is limited due to immune suppression and poor persistence. Immunostimulatory fusion protein (IFP) constructs have been advanced as a tool convert suppressive signals into stimulation thus promote persistence cells, but no universal IFP design has established so far. We now took advantage PD-1-CD28 clinically relevant structure define key determinants activity. Methods compared different variants in human leukemia...
Background Melanoma is an immune sensitive disease, as demonstrated by the activity of check point blockade (ICB), but many patients will either not respond or relapse. More recently, tumor infiltrating lymphocyte (TIL) therapy has shown promising efficacy in melanoma treatment after ICB failure, indicating potential cellular therapies. However, TIL comes with manufacturing limitations, product heterogeneity, well toxicity problems, due to transfer a large number phenotypically diverse T...
Despite recent advances in the targeted therapy of AML, disease continues to have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (alloSCT) remains be curative option for fit patients with high-risk disease. Especially relapsed or refractory (r/r) AML continue outcomes. Myeloablative total body irradiation (TBI) based conditioning can used multiple lines standard therapy, but optimal regimen unclear considered chemotherapy- refractory. Feasibility C-X-C-motif chemokine...
<h3>Background</h3> CAR T cell therapy is remarkably successful in patients with hematological malignancies, some cases inducing durable remissions. However, it remains ineffective solid tumors, part due to poor infiltration into the tumor mass. Determinants of site remain be defined. In contrast, tumors actively attract regulatory (T<sub>reg</sub>) cells for immune suppression through C-C chemokine receptor 8 (CCR8) - CCL1 axis. As this axis functional across cancer entities, we postulated...
Abstract Background Lung cancer patients are at a particularly high risk for brain metastases, and considerable number of affected succumb due to their intracranial disease. Chimeric Antigen Receptor (CAR) T-cells emerged as powerful class cell-based immunotherapy hematological malignancies. However, it remains unclear whether CAR also represent safe effective therapeutic option metastases. Material Methods A fully syngeneic orthotopic cerebral metastasis model in mice was established by...
Abstract BACKGROUND Lung cancer patients are at a high risk for brain metastases, and affected frequently succumb to their intracranial disease. Chimeric Antigen Receptor (CAR) T-cells emerged as powerful cell-based immunotherapy hematological malignancies; however, it remains unclear whether CAR represent viable therapeutic avenue metastases. METHODS A fully immunocompetent, orthotopic cerebral metastasis model was established in mice by combining chronic cranial window with repetitive...
<h3>Background</h3> Despite remarkable response rates mediated by anti-CD19 chimeric antigen receptor (CAR) T cells in selected B cell malignancies, CAR therapy still lacks efficacy the vast majority of tumors. A substantial limiting factor function is immunosuppressive tumor microenvironment. Among other mechanisms, accumulation adenosine within can contribute to disease progression suppressing anti-tumor immune responses. Adenosine 2a- and 2b-receptor (A2<sub>A</sub>...
<h3>Background</h3> The efficacy of chimeric antigen receptor (CAR) T cells against solid tumors remains unsatisfactory due to impaired trafficking the CAR into tumor microenvironment (TME) and presence immunosuppressive factors cells. 5'- triphosphate double-stranded RNA (3p-RNA) is recognized by intracellular pattern recognition retinoic acid-induced gene I (RIG-I). RIG-I activates a downstream signaling cascade, triggering expression type interferons (IFN), proinflammatory cytokines...
<h3>Background</h3> CAR T cell therapy remains ineffective in solid tumors. Scarce infiltration and suppression at the tumor site are two notable limitations. regulatory (Treg) cells capable of suppressing effective anti-tumor responses through inhibitory factors such as transforming growth factor β (TGF-β). Treg expressing C-C chemokine receptor 8 (CCR8) have been found to accumulate correlate with poor prognosis breast cancer. We postulated that CCR8 could be exploited redirect effector...